Frontal fibrosing alopecia. A study of 12 cases in Argentina

Authors

  • Roxana Anastasia Mallo General Interzonal Acute Hospital Eva Perón, San Martín, Buenos Aires, Argentina
  • Fernanada R. Cañón General Interzonal Acute Hospital Eva Perón, San Martín, Province of Buenos Aires
  • Daniela Caratozzolo General Interzonal Acute Hospital Eva Perón, San Martín, Buenos Aires, Argentina
  • Mariela Recanatti General Interzonal Acute Hospital Eva Perón, San Martín, Buenos Aires, Argentina
  • Bruno Ferrari Darma Medical Center, General Pico, La Pampa, Argentina
  • Gimena A. Castro Pérez General Interzonal Acute Hospital Eva Perón, San Martín, Buenos Aires, Argentina

Keywords:

Frontal fibrosing alopecia, lichen planopilaris, cicatricial alopecia, PPAR, pioglitazone, dutasteride

Abstract

Frontal fibrosing alopecia (FFA) is a primary scarring alopecia that typically affects postmenopausal women and is characterized by the recession of the frontal-parieto-temporal hairline with total or partial loss of eyebrows. It is an entity of chronic course with uncertain evo-lution. There are currently no internationally validated clinical-prog-nostic evaluation criteria, although a classification for this purpose has recently been proposed based on a large multicentric casuistry.

Objective: To describe the clinical and demographic characteristics of patients diagnosed with FFA assessed in two Argentine centers.

Design: Retrospective study of 12 patients with FFA evaluated be-tween August 2015 and August 2017 at the Dermatology Service of HIGA Eva Perón (San Martín, Provincia de Buenos Aires) and a private medical center (General Pico, La Pampa).

Materials and methods: The inclusion criteria was the presence of frontal-parietol-temporal recession of the hair implantation line asso-ciated to one of the following: characteristic changes of FFA (perifollicular erythema and hyperkeratosis and closure of follicular openings) and/or scalp biopsy compatible with lymphocytic scar alopecia.

Results: Twelve patients were evaluated in 2 years. All female, meno-pausal and with average age of diagnosis 69 years. Total or partial eye-brows involvement was observed in 100% of cases. The most frequent clinical pattern was the linear pattern (75%) followed by diffuse pattern (17%). All were treated with 5-alpha reductase inhibitors and top-ical minoxidil and 42% received periodic intralesional triamcinolone.

Conclusions: The cohort studied presented a mean age of diagnosis higher than the reported, but with clinical characteristics similar to those published in the international literature.

Limitations: The retrospective nature of the study and the size of the sample.

Author Biographies

Roxana Anastasia Mallo, General Interzonal Acute Hospital Eva Perón, San Martín, Buenos Aires, Argentina

Dermatology Service

Fernanada R. Cañón, General Interzonal Acute Hospital Eva Perón, San Martín, Province of Buenos Aires

Dermatology Service

Daniela Caratozzolo, General Interzonal Acute Hospital Eva Perón, San Martín, Buenos Aires, Argentina

Dermatology Service

Mariela Recanatti, General Interzonal Acute Hospital Eva Perón, San Martín, Buenos Aires, Argentina

Dermatology Service

Bruno Ferrari, Darma Medical Center, General Pico, La Pampa, Argentina

Medical director

Gimena A. Castro Pérez, General Interzonal Acute Hospital Eva Perón, San Martín, Buenos Aires, Argentina

Head of the Dermatology Service

References

I. Kossard S. Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution. Arch Dermatol 1994;30:770-774.

II. Vaño-Galvan S, Molina-Ruiz AM, Serrano-Falcón C, Arias-Santiago S, et ál. Frontal fibrosing alopecia: a multicentric review of 355 patients. J Am Acad Dermatol 2014;70:670-678.

III. Tolkachjov SN, Chaudhry HM, Camilleri MJ, Torgerson RR. Frontal fibrosing alopecia among men: A clinicopathologic study of 7 cases. J Am Acad Dermatol 2017;77:686-690.

IV. Ormaechea-Pérez N, López-Pestaña A, Subizarreta-Salvador J, Jaka-Moreno A, et ál. Alopecia frontal fibrosante en el varón: Presentación de 12 casos y revisión de la literatura. Actas Dermosifiliol 2016;107:836-844.

V. Moreno-Arrones OM, Saceda-Corralo D, Fonda-Pascual P, Rodríguez-Barata AR, et ál. Frontal fibrosing alopecia: clinical and pronostic classification. J Eur Acad Dermatol Venereol2017;31:1739-1745.

VI. Cappetta M, Hernández M, , Lucía Fiesta, Julieta Arbat, et ál. Alopecia fibrosante frontal. Dermatol Argent 2015;21:32-38.

VII. Ladizinski B, Bazakas A, Selim MA, Olsen EA. Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University. J Am Acad Dermatol 2013;68:749-755.

VIII. Tosti A, Miteva M, Torres F. Lonely hair: a clue to the diagnosis of frontal fibrosing alopecia. Arch Dermatol 2011;147:1240.

IX. MacDonald A, Clark C, Holmes S. Frontal fibrosing alopecia: a review of 60 cases. J Am Acad Dermatol 2012;67:955-961.

X. Pirmez R, Donati A, Valente NS, Sodré ST, et ál. Glabellar red dots in frontal fibrosing alopecia: a further clinical sign of vellus follicle involvement. Br J Dermatol 2014;170:745-746.

XI. López-Pestaña A, Tuneu A, Lobo C, Ormaechea N, et ál. Facial lesions in frontal fibrosing alopecia (FFA): Clinicopathological features in a series of 12 cases. J Am Acad Dermatol2015;73:987-992.

XII. Samrao A, Chew AL, Price V. Frontal fibrosing alopecia: a clinical review of 36 cases. Br J Dermatol 2010;163:1296-1300.

XIII. Ma SA, Imadojemu S, Beer K, Seykora JT. Inflammatory features in frontal fibrosing alopecia. J Cutan Pathol 2017;44:672-676.

XIV. Donovan JC. Finasteride-mediated hair regrowth and reversal atrophy in a patient with frontal fibrosing alopecia. JAAD Case Rep 2015;6:353-355.

XV. Mardones F, Shapiro J. Lichen planopilaris in Latin American (Chilean) population: demographics, clinical profile and treatment experience. Clin Exp Dermatol 2017;42:755-759.

XVI. Ferting R, Tosti A. Frontal fibrosing alopecia treatment options. Intractable Rare Dis Res 2016;5:314-315.

XVII. Karnik P, Tekeste Z, McCormick TS, Guilliam AC, et ál. Hair follicle stem cell-specific PPAR-gamma deletion causes scarring alopecia. J Invest Dermatol 2009;129:1243-1257.

XVIII. Ramot I, Mastrofrancesco A, Camera E, Desreumaux P, et ál. The role of PPAR g-signaling in skin biology and pathology: new targets and opportunities for clinical dermatology. Exp Dermatol 2015;24:245-251.

XIX. Mirmirani P, Karnik P. Lichen planopilaris treated with an activator-peroxisome proliferator receptor gamma agonist. Arch Dermatol 2009;145:1363-1366.

Published

2018-06-20

Issue

Section

Original Articles